Cancer immunotherapy has become one of the mainstream treatments for many types of cancer.
anti-PD-1 antibody is intended to release the potential of human T-cells to kill tumors by eliminating immunosuppression mediated by PD-1 signaling pathologies.
, there are other ingredients that inhibit T-cell activity in the tumor micro-environment, including a variety of immunosuppressive cells.
IO102 and IO103 are "first-in-class" immunomodulation vaccines developed by IO Biotech, based on IO Biotech's proprietary T-win technology platform.
the platform is to stimulate T-cell responses that target and directly kill immunosuppressive and tumor cells by injecting a vaccine.
IO102 is designed to activate specific T cells that target IDO proteins, while IO103 activates specific T cells that target PD-L1.
specific T cells that are activated can kill immunosuppressive and tumor cells that express IDO and PD-L1. The immunomodulation vaccine developed by the
T-win technology platform directly kills specific T-cell responses to targeted immunosuppressive and tumor cells (Photo: IO Biotech.com) This breakthrough therapy was awarded based on data from Phase 1/2 clinical trials, with 30 metastases receiving IO102, IO103 and anti-PD-1 antibody therapy.
the IO102 and IO103 vaccines combined with nivolumab have encouraging early efficacy data, according to data recently published in the latest summary of the Virtual Congress of the European EsMO.
combined therapy achieved a total remission rate (ORR) of 79% and 45% of patients received complete remission (CR).
resources: the Food and Drug Administration (FDA) grants IO Biotech background therapy designation for IO102 and IO103 in integration with anti-PD-1 in unresectable/metast melanoma. Retrieved December 16, 2020, from